Concepts (239)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Cost-Benefit Analysis | 9 | 2019 | 2259 | 1.50 | Why? |
| West Nile Fever | 3 | 2018 | 166 | 1.32 | Why? |
| Ontario | 15 | 2021 | 1966 | 1.02 | Why? |
| Health Resources | 3 | 2020 | 2592 | 0.98 | Why? |
| Lyme Disease | 2 | 2019 | 102 | 0.84 | Why? |
| Health Care Costs | 2 | 2019 | 1007 | 0.83 | Why? |
| Palivizumab | 1 | 2019 | 32 | 0.78 | Why? |
| Hepatitis A Vaccines | 1 | 2019 | 52 | 0.75 | Why? |
| Perinatology | 1 | 2017 | 59 | 0.69 | Why? |
| Hepatitis A | 1 | 2019 | 140 | 0.66 | Why? |
| Measles | 2 | 2019 | 608 | 0.54 | Why? |
| Surge Capacity | 1 | 2020 | 894 | 0.47 | Why? |
| Decision Support Techniques | 3 | 2020 | 903 | 0.46 | Why? |
| Immunization Programs | 3 | 2019 | 2006 | 0.44 | Why? |
| Perinatal Care | 1 | 2017 | 576 | 0.44 | Why? |
| Hospitals | 3 | 2020 | 11793 | 0.43 | Why? |
| Residence Characteristics | 1 | 2021 | 1927 | 0.41 | Why? |
| Canada | 10 | 2021 | 6018 | 0.39 | Why? |
| Respiratory Syncytial Virus Infections | 1 | 2019 | 1234 | 0.39 | Why? |
| Quality-Adjusted Life Years | 4 | 2019 | 511 | 0.38 | Why? |
| Hospital Bed Capacity | 3 | 2020 | 1300 | 0.36 | Why? |
| Ventilators, Mechanical | 1 | 2020 | 2193 | 0.34 | Why? |
| Markov Chains | 5 | 2021 | 502 | 0.33 | Why? |
| Schools | 3 | 2021 | 4187 | 0.32 | Why? |
| Decision Making | 1 | 2020 | 3132 | 0.31 | Why? |
| Communicable Diseases | 1 | 2020 | 2148 | 0.30 | Why? |
| Health Services Needs and Demand | 1 | 2020 | 3419 | 0.29 | Why? |
| Models, Theoretical | 2 | 2020 | 6659 | 0.29 | Why? |
| Delivery of Health Care | 2 | 2020 | 15909 | 0.27 | Why? |
| Models, Statistical | 2 | 2020 | 5312 | 0.26 | Why? |
| Clinical Decision-Making | 1 | 2017 | 3755 | 0.26 | Why? |
| Quality of Life | 4 | 2019 | 9820 | 0.22 | Why? |
| Health Policy | 1 | 2020 | 6242 | 0.21 | Why? |
| Critical Care | 2 | 2021 | 14081 | 0.21 | Why? |
| Intensive Care Units | 3 | 2020 | 29594 | 0.19 | Why? |
| Anterior Temporal Lobectomy | 1 | 2018 | 6 | 0.19 | Why? |
| Culicidae | 2 | 2018 | 239 | 0.19 | Why? |
| Contact Tracing | 1 | 2019 | 8448 | 0.19 | Why? |
| Aortic Aneurysm, Abdominal | 1 | 2021 | 155 | 0.18 | Why? |
| Amygdala | 1 | 2018 | 42 | 0.18 | Why? |
| Epilepsy, Temporal Lobe | 1 | 2018 | 37 | 0.18 | Why? |
| Carcinoma, Hepatocellular | 2 | 2018 | 1222 | 0.18 | Why? |
| Mastocytosis | 1 | 2018 | 80 | 0.17 | Why? |
| Liver Cirrhosis | 2 | 2018 | 1810 | 0.16 | Why? |
| School Teachers | 1 | 2021 | 345 | 0.16 | Why? |
| Public Health | 2 | 2019 | 16359 | 0.15 | Why? |
| Hippocampus | 1 | 2018 | 237 | 0.15 | Why? |
| Disease Outbreaks | 3 | 2019 | 27595 | 0.15 | Why? |
| Colombia | 1 | 2020 | 1241 | 0.15 | Why? |
| Waiting Lists | 2 | 2021 | 1388 | 0.15 | Why? |
| Measles virus | 1 | 2017 | 194 | 0.15 | Why? |
| Wet Macular Degeneration | 1 | 2017 | 102 | 0.15 | Why? |
| Computer Simulation | 2 | 2021 | 4982 | 0.15 | Why? |
| Data Interpretation, Statistical | 1 | 2019 | 657 | 0.14 | Why? |
| Respiratory Syncytial Viruses | 1 | 2019 | 612 | 0.14 | Why? |
| Hospitalization | 4 | 2021 | 54280 | 0.14 | Why? |
| Bacteriological Techniques | 1 | 2017 | 239 | 0.14 | Why? |
| Carbapenem-Resistant Enterobacteriaceae | 1 | 2017 | 214 | 0.14 | Why? |
| Humans | 40 | 2021 | 930598 | 0.13 | Why? |
| Mobile Health Units | 1 | 2020 | 741 | 0.13 | Why? |
| Cardiology Service, Hospital | 1 | 2020 | 602 | 0.13 | Why? |
| Nigeria | 1 | 2020 | 2292 | 0.13 | Why? |
| Biological Therapy | 1 | 2017 | 456 | 0.12 | Why? |
| Angiogenesis Inhibitors | 1 | 2017 | 395 | 0.12 | Why? |
| Child, Preschool | 4 | 2021 | 36283 | 0.12 | Why? |
| Pneumococcal Vaccines | 1 | 2018 | 571 | 0.12 | Why? |
| Carcinoma, Renal Cell | 1 | 2018 | 545 | 0.12 | Why? |
| Antineoplastic Agents, Immunological | 1 | 2018 | 830 | 0.11 | Why? |
| Pneumococcal Infections | 1 | 2018 | 562 | 0.11 | Why? |
| Travel-Related Illness | 1 | 2019 | 1357 | 0.11 | Why? |
| Health Expenditures | 1 | 2019 | 904 | 0.11 | Why? |
| Enterobacteriaceae Infections | 1 | 2017 | 529 | 0.11 | Why? |
| Child | 8 | 2021 | 70012 | 0.11 | Why? |
| Visual Acuity | 1 | 2017 | 790 | 0.10 | Why? |
| Kidney Neoplasms | 1 | 2018 | 832 | 0.10 | Why? |
| Regression Analysis | 1 | 2017 | 2484 | 0.10 | Why? |
| Liver Neoplasms | 2 | 2018 | 1666 | 0.10 | Why? |
| Alberta | 2 | 2021 | 375 | 0.10 | Why? |
| Delayed Diagnosis | 1 | 2019 | 1529 | 0.10 | Why? |
| Clostridium Infections | 1 | 2017 | 595 | 0.10 | Why? |
| Hepatitis C, Chronic | 1 | 2018 | 973 | 0.10 | Why? |
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2017 | 877 | 0.09 | Why? |
| Survival Rate | 2 | 2021 | 9206 | 0.09 | Why? |
| Antiviral Agents | 2 | 2019 | 41703 | 0.09 | Why? |
| Cohort Studies | 5 | 2019 | 36005 | 0.09 | Why? |
| Israel | 1 | 2017 | 2751 | 0.09 | Why? |
| Crohn Disease | 1 | 2017 | 959 | 0.09 | Why? |
| Workplace | 1 | 2021 | 2075 | 0.09 | Why? |
| Hepatitis C | 1 | 2019 | 1514 | 0.09 | Why? |
| Infant, Newborn | 2 | 2021 | 23105 | 0.09 | Why? |
| Cost of Illness | 1 | 2019 | 1903 | 0.09 | Why? |
| Pandemics | 6 | 2021 | 389249 | 0.09 | Why? |
| Adolescent | 6 | 2021 | 86841 | 0.09 | Why? |
| Young Adult | 6 | 2021 | 93724 | 0.08 | Why? |
| Databases, Factual | 2 | 2019 | 6248 | 0.08 | Why? |
| Neurosurgical Procedures | 1 | 2018 | 1738 | 0.08 | Why? |
| Vaccination | 4 | 2019 | 19050 | 0.08 | Why? |
| Hyperthermia, Induced | 2 | 1997 | 106 | 0.08 | Why? |
| Time Factors | 3 | 2020 | 31397 | 0.08 | Why? |
| Universities | 1 | 2021 | 4374 | 0.07 | Why? |
| Health Care Rationing | 1 | 2020 | 2558 | 0.07 | Why? |
| Genotype | 1 | 2017 | 4697 | 0.07 | Why? |
| Diagnostic Tests, Routine | 1 | 2017 | 2643 | 0.07 | Why? |
| Carrier State | 1 | 2017 | 2100 | 0.07 | Why? |
| Acute Disease | 1 | 2017 | 6029 | 0.07 | Why? |
| Sex Factors | 1 | 2021 | 11014 | 0.06 | Why? |
| Models, Biological | 1 | 2021 | 4907 | 0.06 | Why? |
| Aged | 9 | 2021 | 215776 | 0.06 | Why? |
| Adult | 10 | 2021 | 244371 | 0.06 | Why? |
| Ambulatory Care | 1 | 2020 | 4947 | 0.06 | Why? |
| Middle Aged | 10 | 2021 | 270681 | 0.06 | Why? |
| Female | 12 | 2021 | 380317 | 0.06 | Why? |
| Students | 1 | 2021 | 5255 | 0.06 | Why? |
| Ultrasonography | 1 | 2018 | 4409 | 0.06 | Why? |
| Aged, 80 and over | 4 | 2021 | 88759 | 0.06 | Why? |
| Research Design | 1 | 2019 | 5830 | 0.06 | Why? |
| Longitudinal Studies | 1 | 2017 | 9893 | 0.06 | Why? |
| Patient Discharge | 1 | 2017 | 5696 | 0.05 | Why? |
| Epidemics | 1 | 2021 | 6407 | 0.05 | Why? |
| Infant | 2 | 2021 | 30274 | 0.05 | Why? |
| Aortic Rupture | 1 | 2021 | 64 | 0.05 | Why? |
| Population Surveillance | 1 | 2017 | 4967 | 0.05 | Why? |
| Male | 10 | 2021 | 367725 | 0.05 | Why? |
| Mass Screening | 2 | 2018 | 8005 | 0.05 | Why? |
| Travel | 1 | 2019 | 7220 | 0.05 | Why? |
| Case-Control Studies | 1 | 2019 | 17671 | 0.05 | Why? |
| Age Factors | 1 | 2021 | 21039 | 0.05 | Why? |
| Borrelia burgdorferi | 1 | 2018 | 31 | 0.05 | Why? |
| Thioguanine | 1 | 2017 | 10 | 0.05 | Why? |
| Mammary Neoplasms, Experimental | 1 | 1997 | 21 | 0.05 | Why? |
| Praseodymium | 1 | 1997 | 1 | 0.04 | Why? |
| Splenic Neoplasms | 1 | 2017 | 20 | 0.04 | Why? |
| Vision, Binocular | 1 | 2017 | 11 | 0.04 | Why? |
| Mercaptopurine | 1 | 2017 | 68 | 0.04 | Why? |
| Risk Assessment | 1 | 2021 | 25439 | 0.04 | Why? |
| Poisson Distribution | 1 | 2018 | 348 | 0.04 | Why? |
| Sustained Virologic Response | 1 | 2018 | 378 | 0.04 | Why? |
| Lymphoma, Mantle-Cell | 1 | 2017 | 109 | 0.04 | Why? |
| West Nile virus | 1 | 2018 | 206 | 0.04 | Why? |
| Lymphoma, Follicular | 1 | 2017 | 109 | 0.04 | Why? |
| Network Meta-Analysis | 1 | 2018 | 426 | 0.04 | Why? |
| Thermometers | 1 | 1997 | 92 | 0.04 | Why? |
| Medical Records | 1 | 2018 | 513 | 0.04 | Why? |
| Respiration, Artificial | 1 | 2021 | 22116 | 0.04 | Why? |
| Occupations | 1 | 2021 | 733 | 0.04 | Why? |
| Seasons | 2 | 2018 | 4071 | 0.04 | Why? |
| Tumor Microenvironment | 1 | 2017 | 264 | 0.04 | Why? |
| Postoperative Period | 1 | 2017 | 651 | 0.04 | Why? |
| Pregnancy | 1 | 2017 | 23879 | 0.04 | Why? |
| Geography | 1 | 2021 | 1801 | 0.04 | Why? |
| Cardiovascular Diseases | 1 | 2020 | 11497 | 0.04 | Why? |
| Serogroup | 1 | 2017 | 510 | 0.04 | Why? |
| Pneumonia, Viral | 2 | 2020 | 243684 | 0.04 | Why? |
| Fibrosis | 1 | 2018 | 800 | 0.03 | Why? |
| Cross Infection | 1 | 2017 | 8675 | 0.03 | Why? |
| Coronavirus Infections | 2 | 2020 | 253789 | 0.03 | Why? |
| Astrocytoma | 1 | 1993 | 29 | 0.03 | Why? |
| Carcinoma | 1 | 1997 | 256 | 0.03 | Why? |
| Public Health Surveillance | 2 | 2018 | 3129 | 0.03 | Why? |
| Risk Factors | 3 | 2018 | 71621 | 0.03 | Why? |
| Bias | 1 | 2019 | 1109 | 0.03 | Why? |
| Lymphokines | 1 | 1992 | 13 | 0.03 | Why? |
| Surveys and Questionnaires | 2 | 2018 | 43792 | 0.03 | Why? |
| Specimen Handling | 2 | 2021 | 6190 | 0.03 | Why? |
| Policy Making | 1 | 2020 | 829 | 0.03 | Why? |
| Climate | 1 | 2018 | 557 | 0.03 | Why? |
| Severity of Illness Index | 2 | 2018 | 48226 | 0.03 | Why? |
| Patient Acuity | 1 | 2019 | 1755 | 0.03 | Why? |
| Animals | 4 | 2018 | 78931 | 0.03 | Why? |
| Costs and Cost Analysis | 1 | 2017 | 694 | 0.03 | Why? |
| Influenza, Human | 1 | 2017 | 10779 | 0.03 | Why? |
| Clinical Laboratory Techniques | 1 | 2019 | 23402 | 0.03 | Why? |
| Linear Models | 1 | 2018 | 1914 | 0.03 | Why? |
| Temperature | 2 | 2018 | 2305 | 0.03 | Why? |
| Glioblastoma | 1 | 1993 | 187 | 0.03 | Why? |
| Immunization Schedule | 1 | 2018 | 1305 | 0.03 | Why? |
| Communicable Disease Control | 1 | 2020 | 29620 | 0.03 | Why? |
| Cerebrovascular Circulation | 1 | 1993 | 340 | 0.03 | Why? |
| United States | 1 | 2017 | 46150 | 0.03 | Why? |
| Organizational Innovation | 1 | 2020 | 2468 | 0.02 | Why? |
| History, 21st Century | 1 | 2017 | 1849 | 0.02 | Why? |
| Resource Allocation | 1 | 2021 | 1771 | 0.02 | Why? |
| Blood-Brain Barrier | 1 | 1993 | 531 | 0.02 | Why? |
| Exanthema | 1 | 2018 | 1097 | 0.02 | Why? |
| Sequence Analysis, DNA | 1 | 2017 | 2830 | 0.02 | Why? |
| Recurrence | 1 | 2017 | 3675 | 0.02 | Why? |
| Early Detection of Cancer | 1 | 2018 | 1956 | 0.02 | Why? |
| Endoscopy | 1 | 2017 | 1564 | 0.02 | Why? |
| Brain Neoplasms | 1 | 1993 | 669 | 0.02 | Why? |
| Consensus | 1 | 2021 | 6345 | 0.02 | Why? |
| Incidence | 2 | 2018 | 25622 | 0.02 | Why? |
| Time-to-Treatment | 1 | 2021 | 5883 | 0.02 | Why? |
| Liver | 1 | 2018 | 4007 | 0.02 | Why? |
| Socioeconomic Factors | 1 | 2021 | 8495 | 0.02 | Why? |
| Liver Transplantation | 1 | 2018 | 2864 | 0.02 | Why? |
| Lymphocyte Activation | 1 | 1992 | 2742 | 0.01 | Why? |
| Triage | 1 | 2021 | 7151 | 0.01 | Why? |
| Algorithms | 1 | 2018 | 7346 | 0.01 | Why? |
| Reproducibility of Results | 1 | 2018 | 11304 | 0.01 | Why? |
| Inpatients | 1 | 2017 | 5161 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2018 | 17020 | 0.01 | Why? |
| Disease Management | 1 | 2018 | 6841 | 0.01 | Why? |
| Betacoronavirus | 2 | 2020 | 204454 | 0.01 | Why? |
| Length of Stay | 1 | 2017 | 11042 | 0.01 | Why? |
| Mice, Inbred C3H | 1 | 1997 | 102 | 0.01 | Why? |
| Retrospective Studies | 2 | 2021 | 105322 | 0.01 | Why? |
| Magnetics | 1 | 1997 | 66 | 0.01 | Why? |
| Diffusion | 1 | 1997 | 73 | 0.01 | Why? |
| Sensitivity and Specificity | 1 | 2018 | 22971 | 0.01 | Why? |
| Phantoms, Imaging | 1 | 1997 | 146 | 0.01 | Why? |
| Lasers | 1 | 1997 | 132 | 0.01 | Why? |
| Artifacts | 1 | 1997 | 250 | 0.01 | Why? |
| Prognosis | 1 | 2018 | 32490 | 0.01 | Why? |
| T-Lymphocytes | 1 | 1992 | 6670 | 0.01 | Why? |
| Pentetic Acid | 1 | 1993 | 2 | 0.01 | Why? |
| Gadolinium DTPA | 1 | 1993 | 45 | 0.01 | Why? |
| Tetradecanoylphorbol Acetate | 1 | 1992 | 23 | 0.01 | Why? |
| China | 1 | 2020 | 50654 | 0.01 | Why? |
| Concanavalin A | 1 | 1992 | 19 | 0.01 | Why? |
| Interleukin-5 | 1 | 1992 | 138 | 0.01 | Why? |
| Nucleic Acid Hybridization | 1 | 1992 | 140 | 0.01 | Why? |
| Emergency Service, Hospital | 1 | 2017 | 14232 | 0.01 | Why? |
| Magnetic Resonance Spectroscopy | 1 | 1997 | 881 | 0.01 | Why? |
| Treatment Outcome | 1 | 2018 | 51732 | 0.01 | Why? |
| Organometallic Compounds | 1 | 1993 | 206 | 0.01 | Why? |
| Interleukin-4 | 1 | 1992 | 367 | 0.01 | Why? |
| Interleukin-2 | 1 | 1992 | 443 | 0.01 | Why? |
| RNA, Viral | 1 | 2017 | 32276 | 0.01 | Why? |
| In Vitro Techniques | 1 | 1992 | 1027 | 0.01 | Why? |
| Spleen | 1 | 1992 | 877 | 0.01 | Why? |
| Contrast Media | 1 | 1993 | 1011 | 0.01 | Why? |
| Mice | 2 | 1997 | 21357 | 0.00 | Why? |
| Interferon-gamma | 1 | 1992 | 2711 | 0.00 | Why? |
| Mice, Inbred BALB C | 1 | 1992 | 5814 | 0.00 | Why? |
| Immunologic Memory | 1 | 1992 | 3362 | 0.00 | Why? |
| RNA, Messenger | 1 | 1992 | 5131 | 0.00 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 1992 | 4545 | 0.00 | Why? |
| Magnetic Resonance Imaging | 1 | 1993 | 6551 | 0.00 | Why? |
| Prospective Studies | 1 | 1993 | 43301 | 0.00 | Why? |
Sander's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(239)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(86)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_